Thai Medical Council on Nov 12 cites 83% infection-free rate in small weekly dengue pill trial
Thailand’s Medical Council highlights a small trial of weekly mosnodenvir for dengue prevention, with larger studies still needed.
- The Thai Medical Council reported that an experimental weekly pill, mosnodenvir, demonstrated an 83% infection-free rate in a small, preliminary study.
- This 83% rate was observed in weekly-dose groups where five out of six volunteers showed no signs of infection after being exposed to the dengue virus, compared to 100% infection in the placebo group.
- The phase 2a trial tested the drug as a preventative measure (prophylaxis) taken before exposure and found no clinically significant safety concerns.
- The council cautioned that the drug is still investigational and that these encouraging results must be confirmed in larger studies before it can be approved.
The Medical Council of Thailand highlighted preliminary findings on November 12, 2026, suggesting that weekly doses of the experimental antiviral mosnodenvir could prevent dengue infection. In a small controlled study, five of six volunteers in each weekly-dose group, or 83%, showed no signs of infection after exposure to dengue virus.
The Medical Council presented the findings in episode 308 of its public health education series, Mor Chuan Ru, citing research published in the New England Journal of Medicine.
The mosnodenvir research examined prevention through medication taken before exposure to the virus. The study did not establish whether the drug could treat patients who had already developed dengue symptoms.
Controlled mosnodenvir study compared four dosing groups
The phase 2a mosnodenvir study compared daily dosing, higher-dose weekly treatment, lower-dose weekly treatment and a placebo, with six participants in each group.
Volunteers in the mosnodenvir study received initial loading doses over two days to establish sufficient drug concentrations in the bloodstream, followed by their assigned maintenance regimen for 21 days.
On the first day of maintenance dosing, participants in the controlled study were injected with an attenuated dengue type 3 virus. Researchers monitored safety, drug concentrations, viral activity and antibody responses for up to 120 days.
Both weekly mosnodenvir groups recorded five of six participants without signs of infection, defined by the absence of detectable viral RNA and dengue antibodies. The daily-dose group recorded four of six participants, or 67%, without signs of infection, while all six placebo recipients became infected.
Mosnodenvir concentrations rose rapidly after the loading doses and were maintained during the maintenance period. The study identified no clinically significant safety concerns.
Mosnodenvir targets proteins needed for dengue replication
Mosnodenvir interferes with the interaction between two viral non-structural proteins, NS3 and NS4B, which help assemble the machinery dengue virus uses to reproduce inside human cells.
By disrupting that interaction, mosnodenvir inhibits the copying of viral RNA, potentially stopping the virus from multiplying sufficiently to cause illness.
Preclinical research has demonstrated mosnodenvir’s activity against all four dengue virus serotypes. The controlled human study discussed by the Medical Council tested protection specifically against type 3.
Breakthrough dengue infections reveal viral changes
Researchers identified new amino acid changes in the NS4B protein in all four mosnodenvir recipients with breakthrough infections and available sequencing data. Changes were also found in two of the six infected placebo recipients.
Among mosnodenvir recipients, the changes included A19L in one participant, V91G in two, L94F in one and Y99H in one. The placebo group had S60I in one participant and I201V in another.
The Medical Council identified the NS4B findings as an issue requiring further investigation into possible drug resistance and appropriate dosing. Detecting a viral change does not, by itself, establish its clinical effect on resistance.
The Medical Council also reported that approximately 900 people had received mosnodenvir across studies, with no clinically significant safety concerns identified to date.
Weekly dengue prevention requires larger field studies
The Medical Council cautioned that mosnodenvir requires further testing in larger populations and areas with natural dengue transmission. The drug remains investigational.
A two-day loading period followed by weekly maintenance doses could make mosnodenvir more practical for people travelling to high-risk areas at short notice, according to the council.
Potential beneficiaries identified by the Medical Council include travellers and workers making short visits to areas with substantial transmission, as well as residents of communities experiencing sudden outbreaks. The council compared preventive antiviral use with taking malaria prophylaxis before entering a risk area.
The Medical Council cited estimates of approximately 400 million dengue infections annually, including around 100 million symptomatic cases, with nearly four billion people in more than 129 countries at risk.
The council also highlighted Florida’s outbreak, citing 485 locally acquired cases reported by October 24, 2026, including 60 in the latest reporting week, compared with 62 locally acquired cases in 2025. Its account noted the death of an 80-year-old patient.
There is currently no approved antiviral medicine specifically for dengue prevention or treatment. The Medical Council described the mosnodenvir findings as an encouraging step towards a first oral preventive antiviral, while emphasising that larger studies are still needed.
